WASHINGTON — An investigational single-pill regimen for HIV — the first to be based on a protease inhibitor — was less toxic than a similar regimen using separate drugs, researchers said here.

In a phase II, placebo-controlled, randomized trial, the single-pill regimen also yielded the same efficacy as the multi-pill regimen over 48 weeks of treatment, according to Anthony Mills, MD, of the Southern California Men’s Medical Group in Los Angeles.

Aside from their formulation, the two regimens include mostly the same drugs, Mills said at the Interscience Conference on Antimicrobial Agents and Chemotherapy.

READ FULL ARTICLE Curated publisher From Medical Page Today